Skip to main content
    1

    10X Genomics Inc (TXG)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $54.99
    -3.20 (-5.50%)

    Market Cap: $7.65B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    10X Genomics Inc (TXG) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect 10X Genomics (TXG) to earn $0.06 per share in the fiscal year ending Dec 31, 2026, on revenue of $631.04M. Of 17 analysts, 6 rate the stock Buy or Strong Buy, 11 Hold and 0 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.09.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.59, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 35% of the ratings.

    RatingAnalystsShare
    Strong Buy15.9%
    Buy529.4%
    Hold1164.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Hold
    Total analysts
    17

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 50.0% and revenue estimates rise 11.7%.

    Fiscal year ending Dec 31, 2026
    $0.06
    EPS consensus, revenue $631.04M
    Fiscal year ending Dec 31, 2027
    $0.09
    EPS consensus, revenue $705.00M
    Next report
    Feb 10, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.06-$0.10 to $0.183$631.04M$627.30M to $635.01M14
    Dec 31, 2027$0.09$0.01 to $0.203$705.00M$663.09M to $746.50M15

    Quarterly Estimates

    The EPS consensus rises from -$0.22 for the quarter ending Dec 31, 2026 to -$0.03 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.22-$0.33 to -$0.0716$179.68M$163.56M to $190.99M17
    Mar 31, 2027-$0.03-$0.03 to -$0.031$167.33M$156.88M to $180.00M10

    Estimate Revisions

    PeriodUp 30 daysDown 30 days
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 40.0% from $0.10.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$0.06$0.04$0.04$0.11$0.10-36.7%
    Fiscal year ending Dec 31, 2027$0.09$0.08$0.08$0.20$0.20-57.4%
    Quarter ending Mar 31, 2027-$0.03-$0.03$0.02$0.02$0.01N/A

    Frequently Asked Questions About TXG

    What is the TXG stock forecast?

    Consensus analyst estimates put 10X Genomics's EPS at $0.06 for the fiscal year ending Dec 31, 2026, on revenue of $631.04M. The consensus rating from 17 analysts is Hold.

    How do analysts rate TXG stock?

    Of 17 analysts covering 10X Genomics, 1 rates it Strong Buy, 5 Buy, 11 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from TXG next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.06, with estimates from -$0.10 to $0.18 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.09, with estimates from $0.01 to $0.20 from 3 analysts.

    What revenue do analysts expect from 10X Genomics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $631.04M, with estimates from $627.30M to $635.01M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $705.00M, with estimates from $663.09M to $746.50M.

    How many analysts cover TXG?

    17 analysts rate 10X Genomics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.